PhRMA Statement on First FDA Approval of A Biosimilar Product

PhRMA supports a science-based, transparent implementation of the BPCIA biosimilars pathway.

2005 - 2015: A Decade of Innovation In Rare Diseases

Researching Hepatitis C Medicines: Setbacks and Stepping Stones

Researching Alzheimer’s Medicines: Setbacks and Stepping Stones

The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients

Innovation in the Biopharmaceutical Pipeline: A Multidimensional View

A new study by the Analysis Group details how the U.S. biopharmaceutical industry leads the world in development of new medicines, with over 300 new prescription medicines approved by the U.S. Food and Drug Administration (FDA) over the past decade.

Researching Alzheimer's Medicines

Alzheimer’s disease is among the most devastating diseases anyone can face. Learn about how researchers are advancing treatment options and the challenges they face.

View the Report

New Medicines Approvals in 2013

In 2013, the Food and Drug Administration (FDA) approved 34 new medicines — down from a 15-year high of 44 in 2012. Of those, 27 were approved by the Center for Drug Evaluation and Research (CDER) and seven by the Center for Biologics Evaluation and Research (CBER). 

View the Report

Researching Cancer Medicines: Setbacks and Stepping Stones

We have seen great advances in the fight against cancer but behind the medicines that make it to patients are many that do not. Learn more about so-called failed medicines and their role in advancing care.

View the Report

Vaccine Fact Book 2013

Vaccine research and development is lengthy and risky. From discovery to license requires 10 to 15 years. Approximately one out of 10 vaccines that enter clinical development will reach the market.

View the Report


Subscribe to RSS - Innovation